 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Introgen Therapeutics, Inc.
 |
Introgen Therapeutics, Inc. |
 |
 |
 |
PROFILE |
 |
Introgen Therapeutics' gene therapy products fight cancer by attempting to restore or correct missing or aberrant gene functions. Working with Aventis, the company is testing its flagship product, INGN 201, as a treatment for head and neck cancer. Introgen also has a research agreement with the National Cancer Institute to conduct clinical studies of INGN 201 for other cancers. In addition to INGN 201, the firm is researching genetic products for treating breast, lung, colorectal, prostate, and other cancers. The company has established a presence in Europe through subsidiary Gendux AB to enhance its connections there. Aventis owns about 20% of the company.
COMPETITION |
 |
Onyx Pharmaceuticals, Inc. (ONXX)
Valentis, Inc. (VLTS)
Vical Incorporated (VICL)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: June
2000 Sales (mil.): 8.40
1-Yr. Sales Growth: 2.6%
Employees: 53
Revenue per employee: $158,490.57
KEY PEOPLE |
 |
David G. Nance
CEO
James W. Albrecht
CFO
CONTACT INFO |
 |
301 Congress Ave., Ste. 1850
Austin, TX 78701
US
Phone: 512-708-9310
Fax: 512-708-9311
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |